Propionic Acid

Propionic Acid

SCHEMBL38600

CCC(=O)O.CCCCCCCCCCCCCCOCCCCCCCCCCCCCC

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.59
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
THRB P10828 1/20 0.58
HTT P42858 1/20 0.58
MAPT P10636 1/20 0.58
NAAA Q02083 1/20 0.56
GPR84 Q9NQS5 7/20 0.52
PPARG P37231 7/20 0.52
PPARD Q03181 7/20 0.52
PPARA Q07869 7/20 0.52
HDAC11 Q96DB2 5/20 0.52
TSHR P16473 4/20 0.52
PTPN1 P18031 3/20 0.52
ALDH1A1 P00352 2/20 0.52
TLR2 O60603 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
FABP4 P15090 2/20 0.52
SLC22A6 Q4U2R8 1/20 0.52
SLC22A8 Q8TCC7 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL11836943 1.00 CES2 (0.59) CES2MEN1KMT2ATHRBHTT
Propionic Acid SCHEMBL3921327 1.00 CES2 (0.59) CES2MEN1KMT2ATHRBHTT
Propionic Acid SCHEMBL27871359 0.98 CES2 (0.57) CES2MEN1KMT2ATHRBHTT
Propionic Acid SCHEMBL11694208 0.98 MEN1 (0.61) CES2MEN1KMT2ATHRBHTT
Propionic Acid SCHEMBL11837630 0.98 CES2 (0.56) CES2MEN1KMT2ATHRBHTT
Propionic Acid SCHEMBL2254834 0.91 MEN1 (0.59) CES2MEN1KMT2ATHRBHTT
Bicarbonate SCHEMBL27976205 0.90 CES2 (0.64) CES2MEN1KMT2ATHRBHTT
Bicarbonate SCHEMBL15512279 0.90 CES2 (0.64) CES2MEN1KMT2ATHRBHTT
Propionic Acid SCHEMBL11837655 0.90 TSHR (0.56) CES2MEN1KMT2ATHRBHTT
Bicarbonate SCHEMBL8198778 0.90 CES2 (0.64) CES2MEN1KMT2ATHRBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1608 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230225987-A1 TOPICAL PHARMACEUTICAL COMPOSITIONS Dermavant Sciences GmbH (CH) 2023-07-20 US claimed
CN-116139029-A Water-in-oil type cool itching-relieving ointment and preparation method thereof 广州翀潇生物科技有限公司 2023-05-23 CN claimed
EP-4171529-A1 TOPICAL PHARMACEUTICAL COMPOSITIONS Dermavant Sciences GmbH (CH) 2023-05-03 EP claimed
WO-2021262917-A1 TOPICAL PHARMACEUTICAL COMPOSITIONS Dermavant Sciences GmbH (CH) 2021-12-30 WO claimed
EP-3820448-A2 TOPICAL DETOMIDINE FORMULATIONS Clexio Biosciences Ltd. (IL) 2021-05-19 EP claimed
US-20210137830-A1 TOPICAL DETOMIDINE FORMULATIONS CLEXIO BIOSCIENCES LTD. (IL) 2021-05-13 US claimed
EP-3496703-B1 MOXIDECTIN TOPICAL LIQUID FORMULATIONS NORBROOK LAB LTD (GB) 2021-05-12 EP claimed
US-10675240-B2 Transdermal cannabinoid formulations MM TECHNOLOGY HOLDINGS, LLC (US) 2020-06-09 US claimed
WO-2020067968-A1 NEW COMPOSITIONS COMPRISING CATECHIN POLYPHENOLS FARMETT LÄKEMEDEL AB (SE) 2020-04-02 WO claimed
WO-2020012415-A2 TOPICAL DETOMIDINE FORMULATIONS CLEXIO BIOSCIENCES LTD. (IL) 2020-01-16 WO claimed
US-6087393-A PREVENTING FROM OXIDATION BY DISPERSING 1-ASCORBIC ACID IN A MIXED GLYCOL CARRIER INCLUDING PROPYLENE GLYCOL, BUTYLENE GLYCOL, AND A STABILIZER IGEN, INC. (US) 2000-07-11 US claimed
EP-0778765-A4 COSMETIC MAKE-UP COMPOSITIONS PROCTER & GAMBLE (US) 2000-04-19 EP claimed
US-6013269-A OIL-IN-WATER EMULSION COMPRISING VOLATILE SILICONE OIL AND/OR VOLATILE HYDROCARBON OIL, NON-VOLATILE OIL, PIGMENT AND ORGANIC AMPHIPHILIC MATERIAL CAPABLE OF FORMING SMECTIC LYOTROPIC LIQUID CRYSTALS IN PRODUCT OR ON THE SKIN THE PROCTER & GAMBLE COMPANY (US) 2000-01-11 US claimed
EP-0778765-A1 COSMETIC MAKE-UP COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1997-06-18 EP claimed
EP-0432494-B1 Pour-on formulations effective for the control of internal and external parasites of homothermic animals AMERICAN CYANAMID CO (US) 1997-02-05 EP claimed
WO-1996011665-A1 COSMETIC MAKE-UP COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1996-04-25 WO claimed
EP-0432494-A2 Pour-on formulations effective for the control of internal and external parasites of homothermic animals AMERICAN CYANAMID COMPANY (US) 1991-06-19 EP claimed
US-4889845-A POLYDIMETHYLSILOXANE MIXTURE; STORAGE STABILITY; E-TYPE PROSTAGLANDINS AMERICAN CYANAMID COMPANY (US) 1989-12-26 US claimed
EP-0249193-A2 Vehicle for topical application of pharmaceuticals AMERICAN CYANAMID COMPANY (US) 1987-12-16 EP claimed
EP-0249194-A2 Topical prostaglandin formulations AMERICAN CYANAMID COMPANY (US) 1987-12-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10675240-B2 Transdermal cannabinoid formulations TNNC1, CNR2, TNNT2 CES2 794/4885MEN1 2000/4885KMT2A 2998/4885
US-20230225987-A1 TOPICAL PHARMACEUTICAL COMPOSITIONS TSLP, SQLE, DHCR7 CES2 3197/4885MEN1 4400/4885KMT2A 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.